Safety and Efficacy of Nivolumab in Patients With Advanced Non–small-cell Lung Cancer Treated Beyond Progression: Clinical Lung Cancer

B. Ricciuti, C. Genova, M. Bassanelli, A. De Giglio, M. Brambilla, G. Metro, S. Baglivo, M.G. Dal Bello, A. Ceribelli, F. Grossi, R. Chiari

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)178-185.e2
JournalClin. Lung Cancer
Volume20
Issue number3
DOIs
Publication statusPublished - 2019

Keywords

  • Nivolumab
  • NSCLC
  • Pseudoprogression
  • RECIST
  • Treatment beyond progression
  • alanine aminotransferase
  • alkaline phosphatase
  • anaplastic lymphoma kinase
  • aspartate aminotransferase
  • bilirubin
  • epidermal growth factor receptor
  • gamma glutamyltransferase
  • nivolumab
  • abdominal pain
  • adult
  • advanced cancer
  • aged
  • anemia
  • anorexia
  • arthralgia
  • Article
  • cancer fatigue
  • cancer growth
  • cancer immunotherapy
  • cancer staging
  • cancer survival
  • colitis
  • constipation
  • controlled study
  • dermatomyositis
  • disease association
  • disease control
  • drug efficacy
  • drug safety
  • drug withdrawal
  • dry skin
  • female
  • human
  • hyperthyroidism
  • hypothyroidism
  • kidney failure
  • major clinical study
  • male
  • nausea
  • neutropenia
  • non small cell lung cancer
  • overall survival
  • pneumonia
  • progression free survival
  • psoriasis
  • rash
  • response evaluation criteria in solid tumors
  • side effect
  • thrombocytopenia
  • treatment duration
  • uveitis
  • vomiting
  • xerostomia

Cite this